TABLE 3

Dose, duration of bile collection, and observed biliary excretion of 25 literature compounds in BDC rats

The mean of the differences is 3.9%, and the mean of the absolute differences is 13% of dose.

CompoundDoseBile CollectionObservationReference
mg/kgh% dose
BMS-18287448120.9Chong et al., 2003
BMS-18734545124.5Chong et al., 2003
BMS-3870328.9911.0Kamath et al., 2005a
Cephradine25627.3Moriwaki et al., 2003
Dasatinib1099.6Kamath et al., 2008
Digitoxin0.01453.7Funakoshi et al., 2003
Digoxin0.081259.0Russell and Klaassen, 1973
DNP-NAC0.05142.0Hinchman et al., 1998
EPE-glucuronide12464.5Payan et al., 1999
Erythromycin<1134.0Akashi et al., 2006
Estradiol-17β-glucuronide<1187.0Akashi et al., 2006
Fexofenadine11.8969.8Kamath et al., 2005b
Irinotecan (lactone form)1047.0Arimori et al., 2003
Irinotecan (carboxylate form)10459.8Arimori et al., 2003
Lissamine fast yellow25.25390.0Hirom et al., 1972b
Methotrexate102.572.0Masuda et al., 1997
7-Hydroxymethotrexate4.03.372.0Fahrig et al., 1989
Olmesartan<1383.0Takayanagi et al., 2005
Ouabain0.081255.0Russell and Klaassen, 1973
Paclitaxel102411.5Monsarrat et al., 1990
Phenolphthalein glucuronide24.8382.0Hirom et al., 1972b
Pravastatin (carboxylate form)<1180.0Kurihara et al., 2005
Sitagliptin2.07216.4Beconi et al., 2007
Vinblastine<11.530.0Kurihara et al., 2005
Vincristine0.5242.6Song et al., 1999
  • BMS-187345, 5-methylamino-N-(3,4-dimethyl-5-isoxaxolyl)-1-naphthalene sulfonamide; BMS-387032, N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4 piperidinecarboxamide; DNP-NAC, S-2,4-dinitrophenyl-N-acetylcystein; EPE, 1-(2′-ethylphenyl)ethanol.